ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,019Medicare Part D Prescriptions Filled, Including Refills

Rank: 466 out of 1499

$400K Total Retail Price of All Prescriptions

Rank: 484 out of 1499

291 Patients Receiving at Least One Drug in Part D
73%Patients 65 Years and Older
48% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Missouri
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 291 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

9% of this provider’s 291 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

2% of this provider’s 5,790 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Missouri
OMEPRAZOLE 327 219 1 5
LEVOTHYROXINE SODIUM 323 265 2 2
LISINOPRIL 246 204 3 1
AMLODIPINE BESYLATE 240 182 4 6
METFORMIN HCL 238 161 5 8
METOPROLOL TARTRATE 195 161 6 10
PRAVASTATIN SODIUM 194 155 7 18
FLUTICASONE PROPIONATE 191 116 8 31
RANITIDINE HCL 180 85 9 15
SIMVASTATIN 167 109 10 3
GABAPENTIN 166 123 11 13
LISINOPRIL-HYDROCHLOROTHIAZIDE 159 85 12 25
FUROSEMIDE 158 151 13 7
LOVASTATIN 129 90 14 19
MELOXICAM 124 92 15 27
HYDROCHLOROTHIAZIDE 123 101 16 9
TRAMADOL HCL 104 71 17 16
DONEPEZIL HCL 100 100 18 35
LANTUS 91 59 19 46
ZOLPIDEM TARTRATE 85 49 20 23
PROAIR HFA 85 42 20 30
MIRTAZAPINE 85 85 20 50
NAMENDA 85 85 20 47
POTASSIUM CHLORIDE 84 64 24 11
CARVEDILOL 81 63 25 22
FLUOXETINE HCL 81 55 25 43
TAMSULOSIN HCL 79 57 27 29
ATORVASTATIN CALCIUM 76 64 28 17
ADVAIR DISKUS 75 37 29 37
CYMBALTA 73 69 30 40
MORPHINE SULFATE ER 73 23 S2 30 85
NAPROXEN 72 53 32 63
AZITHROMYCIN 71 48 33 45
HYDROCODONE-ACETAMINOPHEN 66 56 S3 34 4
ATENOLOL 66 66 34 21
FINASTERIDE 66 60 34 98
SINGULAIR 64 44 37 67
NIASPAN 63 24 38 150
AMITRIPTYLINE HCL 61 33 R 39 49
NEXIUM 60 44 40 28
LOSARTAN-HYDROCHLOROTHIAZIDE 55 43 41 73
SPIRIVA 52 28 42 44
LOSARTAN POTASSIUM 52 37 42 26
MONTELUKAST SODIUM 51 30 44 133
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 18, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.